Navigation Links
Terumo Cardiovascular Group Announces New President and CEO, Robert DeRyke
Date:4/6/2017

ANN ARBOR, Mich., April 6, 2017 /PRNewswire/ -- Terumo Cardiovascular (CV) Group today announced that Robert (Rob) DeRyke has been appointed President and CEO of Terumo CV Group, effective April 1, 2017, following the retirement of long-time President and CEO Mark Sutter. In this position, DeRyke will lead Terumo's global business related to the cardiopulmonary bypass market including Terumo Cardiovascular Systems (CVS), CV Group's operating company in the United States.

Prior to this appointment, DeRyke served as President of Terumo CV Group's Electromechanical (EM) Systems Division. "Under his leadership, Rob brought stability and improved profitability to the business," said Shinjiro Sato, President and CEO of Terumo Corporation, Terumo CV Group's parent company.

Robert (Rob) DeRyke, President and CEO, Terumo Cardiovascular Group
Robert (Rob) DeRyke, President and CEO, Terumo Cardiovascular Group

DeRyke takes lead of a company with deep expertise in the cardiac arena, well positioned for the future.

"We have a strong foundation of talent, technologies, and systems to build on as we deliver long-term value to our customers and their patients," said DeRyke.

Terumo CV Group is building momentum that will create a positive impact for healthcare providers and the critically ill patients they serve.  Having recently cleared the shipping restrictions imposed as a condition of its 2011 consent decree, the company is preparing to return its flagship Terumo® Advanced Perfusion System 1 heart-lung machine to market in June 2017. As a market leader in oxygenators and cardiac monitoring technologies, Terumo CV Group will introduce its newest CAPIOX® oxygenator and CDI® inline blood gas monitoring system later this year, reinforcing the company's commitment to the global cardiac community.

DeRyke joined Terumo in 2012 as Vice President of Corporate Quality for Terumo CVS. He has over 25 years' experience in medical devices and pharmaceuticals, and has held executive leadership positions for Baxter Healthcare, Hospira, and Thermo-Fisher Scientific. He holds a Master of Business Administration from Michigan State University and a Bachelor of Science in Chemistry from Western Michigan University.

About Terumo Cardiovascular Group

Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information, visit www.terumo-cvgroup.com.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Terumo and CAPIOX are registered trademarks of Terumo Corporation. CDI is a registered trademark of Terumo Cardiovascular Systems.

879978

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/terumo-cardiovascular-group-announces-new-president-and-ceo-robert-deryke-300436270.html


'/>"/>
SOURCE Terumo Cardiovascular Group
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp.
2. Global Coronary Stents Market 2014-2018: Key Vendors are Abbott, Boston Scientific, Medtronic and Terumo
3. Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating
4. OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation
5. Abiomed Inc., HeartWare International and Terumo Corporation Battling out for the top Spot in the Cardiac Assist Devices Market
6. MC3 Cardiopulmonary Acquires Surgical Cannula Product Assets from Terumo Cardiovascular Systems
7. Global Coronary Artery Disease Treatment Devices Market 2015-2019 - Key Vendors are Abbott Vascular, Boston Scientific, Medtronic & Terumo
8. Terumo BCT Announces a $17.4 Million Funding Contract from the Biomedical Advanced Research and Development Authority (BARDA)
9. Research and Markets - Global Intravenous (IV) Solutions Market Analysis 2016 - Forecast to 2022 - Key Players are Widatra Bhakti, Vifor Pharma & Terumo
10. Terumo Showcases Radial Access Portfolio at American College of Cardiology Conference
11. The Global Cardiovascular Drugs Market to Decline at a CAGR of 10.47 Percent Over the Period 2012-2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... -- The Cincinnati location of Diplomat ... DPLO), has been awarded a Top Workplaces 2017 ... are based on an employee survey administered by WorkplaceDynamics, LLC, ... The survey measures several aspects of workplace culture, including alignment, ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is in ... red these days. According to recent estimates, 75 – 80% of the medical ... Some studies point to Electronic Health Records (EHR) with automated features designed to ...
(Date:6/25/2017)... CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music video ... above footage and sound in the timeline and write in the lyrics to any song. ... flying back out. Each line of the text can be added modularly for optimal control. ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation ... significant harm to people with all chronic conditions, including mental illnesses, while increasing ... place the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it ...
Breaking Medicine News(10 mins):